Cancers | Free Full-Text | Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Modified low-dose carfilzomib plus dexamethasone treatment protocol... | Download Scientific Diagram
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
Modified low-dose carfilzomib plus dexamethasone treatment protocol... | Download Scientific Diagram
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial | Haematologica
Addition of Daratumumab Increases Benefit of Carfilzomib/Dexamethasone in Multiple Myeloma - The ASCO Post
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design | Future Oncology
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i ...
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial - The Lancet
Treatment With Carfilzomib: A Promising Future for Multiple Myeloma - JADPRO
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma | Blood Cancer Journal
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial - The Lancet
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial | Haematologica
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i ...
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma - ScienceDirect
Dosing and Administration | KYPROLIS® (carfilzomib)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma - Altai Oncology
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS | Blood Cancer Journal
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
